FDA Approves Reduced Monitoring Time for First Two Doses of Amgen's IMDELLTRA for Extensive-Stage Small Cell Lung Cancer

The U.S. Food and Drug Administration (FDA) has approved an update to the IMDELLTRA® (tarlatamab-dlle) Prescribing Information, significantly reducing the recommended monitoring time for the first two doses of treatment from 22-24 hours to 6-8 hours in an appropriate healthcare setting. This change aims to reduce the time patients with extensive-stage small cell lung cancer spend in healthcare settings and simplify treatment for community oncology practices.